222 related articles for article (PubMed ID: 25641339)
21. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
Hurst Z; Liyanarachchi S; He H; Brock P; Sipos J; Nabhan F; Kebebew E; Green P; Cote GJ; Sherman S; Walker CJ; Chang YS; Xue S; Hollingsworth B; Li W; Genutis L; Menq E; de la Chapelle A; Jhiang SM
Thyroid; 2019 Apr; 29(4):530-539. PubMed ID: 30654714
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
Nasir A; Reising LO; Nedderman DM; Fulford AD; Uhlik MT; Benjamin LE; Schade AE; Holzer TR
Anticancer Res; 2016 Jun; 36(6):2683-96. PubMed ID: 27272777
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
[TBL] [Abstract][Full Text] [Related]
24. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
25. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
27. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
Dadu R; Cabanillas ME
Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
[TBL] [Abstract][Full Text] [Related]
28. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
29. Do Molecular Profiles of Primary
Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
[TBL] [Abstract][Full Text] [Related]
31. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
[TBL] [Abstract][Full Text] [Related]
32. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
33. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
34. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
35. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Cohen EE; Tortorici M; Kim S; Ingrosso A; Pithavala YK; Bycott P
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1261-70. PubMed ID: 25315258
[TBL] [Abstract][Full Text] [Related]
36. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
38. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
39. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
40. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
